Sep 23 2026 09:45 PM EST
10x Genomics Boosts Outlook on Atera Orders and Raised FY 2026 Revenue Guidance
10x Genomics (NASDAQ: TXG) saw its shares climb more than 26% in the past month after the company announced that Atera instrument orders already exceed its full‑year shipment target and raised FY 2026 revenue guidance to $610‑$630 million.
Atera Orders and Guidance Upgrade
Management said booked orders for the new Atera platform already surpass the 2026 shipment target of roughly 40 instruments, with most deliveries slated for Q4. The company lifted its FY 2026 revenue outlook to $610‑$630 million, implying 2%‑5% growth over FY 2025 when non‑recurring patent‑litigation settlement revenue is excluded.
Q2 2026 Financial Results
Revenue for the quarter was $151 million, including $1.6 million of Takara settlement royalty; excluding the settlement, revenue was $149 million, a 3% YoY increase. Consumables rose 7% YoY, driven by single‑cell (+3%) and spatial (+16%) lines, while instrument revenue fell 47% YoY as customers paced purchases ahead of the Atera launch.
Gross margin improved to 74% from 72% a year earlier, helped by a $2.6 million tariff refund and lower inventory write‑downs. Operating loss widened to $19.6 million versus an operating income of $30.1 million in Q2 2025, reflecting a flat‑to‑slightly‑higher expense base after stripping out a settlement gain of $3.4 million.
Cash, cash equivalents and marketable securities stood at $552 million at quarter‑end, up $105 million YoY.
Sector Tailwinds
The spatial‑biology market is projected to grow from $1.1 billion in 2025 to $6.0 billion by 2035 (CAGR 18.5%). Single‑cell analysis is forecast to expand from $5.28 billion in 2025 to $10.95 billion by 2031 (CAGR 12.9%). Management highlighted AI‑driven demand for large‑scale biological data as a structural tailwind, citing collaborations with Cleveland Clinic and Lausanne University Hospital to build translational datasets.
Strategic Initiatives
During the quarter the company completed its acquisition of Proteintech Genomics, adding proteomics capability to its multi‑omics roadmap. New product launches—including the GEM‑X Multiome and whole‑blood workflows—aim to broaden the addressable market for the Atera platform. The firm also announced a partnership with Brigham and Women’s Hospital and the Cancer Research Institute to profile 1,000 patients with autoimmune diseases, and an AI‑driven immuno‑oncology initiative targeting >20,000 samples.
Valuation and Investor Positioning
TXG shares have outperformed the market, returning +26.7% over the past month versus the S&P 500’s +3.3%. The stock’s 6‑month price appreciation stands at +321.6%. Institutional ownership is high at roughly 84.7%, with notable holders including Goldman Sachs and RBC. Analyst coverage is mixed: UBS initiated a neutral rating with a $68 target, while Canaccord Genuity raised its target to $60 (Buy). Consensus on MarketBeat.com remains a Hold with a $44 price target.
Risks and Uncertainties
Key risks include the near‑term dip in instrument revenue as customers defer purchases ahead of Atera shipments, potential tariff impacts on APAC sales, and execution risk around scaling Atera manufacturing capacity. The 10‑K lists additional concerns such as visa restrictions for international students, regulatory uncertainty around AI‑driven diagnostics, and the possibility of adverse outcomes in ongoing patent litigation.